Travere Therapeutics, Inc.
TVTX
$42.84
-$0.67-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 536.20M | 490.73M | 435.83M | 333.87M | 273.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 536.20M | 490.73M | 435.83M | 333.87M | 273.53M |
| Cost of Revenue | 248.64M | 228.77M | 232.97M | 232.80M | 238.31M |
| Gross Profit | 287.56M | 261.96M | 202.86M | 101.07M | 35.22M |
| SG&A Expenses | 344.62M | 324.78M | 292.58M | 271.75M | 260.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 593.26M | 553.55M | 525.55M | 504.55M | 498.62M |
| Operating Income | -57.06M | -62.82M | -89.73M | -170.68M | -225.09M |
| Income Before Tax | -44.81M | -49.27M | -88.55M | -169.10M | -225.93M |
| Income Tax Expenses | 829.00K | 988.00K | -5.00K | -97.00K | -32.00K |
| Earnings from Continuing Operations | -45.64 | -50.26 | -88.54 | -169.00 | -225.90 |
| Earnings from Discontinued Operations | 24.22M | 24.72M | 4.00K | -55.00K | -812.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.42M | -25.55M | -88.54M | -169.06M | -226.71M |
| EBIT | -57.06M | -62.82M | -89.73M | -170.68M | -225.09M |
| EBITDA | 16.09M | -2.08M | -35.03M | -120.54M | -178.61M |
| EPS Basic | -0.23 | -0.29 | -1.05 | -2.04 | -2.81 |
| Normalized Basic EPS | -0.31 | -0.35 | -0.64 | -1.26 | -1.73 |
| EPS Diluted | -0.24 | -0.30 | -1.06 | -2.04 | -2.81 |
| Normalized Diluted EPS | -0.33 | -0.37 | -0.67 | -1.26 | -1.73 |
| Average Basic Shares Outstanding | 360.34M | 356.83M | 349.64M | 338.19M | 326.74M |
| Average Diluted Shares Outstanding | 373.73M | 370.21M | 363.03M | 338.19M | 326.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |